Stock DNA
Pharmaceuticals & Biotechnology
CNY 43,394 Million (Large Cap)
23.00
NA
0.51%
0.03
5.60%
1.33
Revenue and Profits:
Net Sales:
2,139 Million
(Quarterly Results - Sep 2025)
Net Profit:
441 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.02%
0%
-8.02%
6 Months
-15.75%
0%
-15.75%
1 Year
-15.07%
0%
-15.07%
2 Years
-10.88%
0%
-10.88%
3 Years
12.28%
0%
12.28%
4 Years
-15.42%
0%
-15.42%
5 Years
-23.61%
0%
-23.61%
Shanghai RAAS Blood Products Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
24.84%
EBIT Growth (5y)
14.99%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.12
Sales to Capital Employed (avg)
0.25
Tax Ratio
18.73%
Dividend Payout Ratio
21.19%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.22%
ROE (avg)
6.49%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
1.40
EV to EBIT
23.90
EV to EBITDA
21.61
EV to Capital Employed
1.39
EV to Sales
5.82
PEG Ratio
3.08
Dividend Yield
1.04%
ROCE (Latest)
5.83%
ROE (Latest)
6.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
2,138.90
1,946.30
9.90%
Operating Profit (PBDIT) excl Other Income
434.30
485.80
-10.60%
Interest
17.40
5.80
200.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
440.70
463.40
-4.90%
Operating Profit Margin (Excl OI)
203.00%
222.90%
-1.99%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 9.90% vs -2.97% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -4.90% vs -18.16% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
8,147.50
7,943.90
2.56%
Operating Profit (PBDIT) excl Other Income
2,308.30
2,482.10
-7.00%
Interest
1.00
0.50
100.00%
Exceptional Items
0.00
-47.50
100.00%
Consolidate Net Profit
2,193.80
1,777.40
23.43%
Operating Profit Margin (Excl OI)
256.70%
290.80%
-3.41%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 2.56% vs 21.31% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 23.43% vs -5.10% in Dec 2023
About Shanghai RAAS Blood Products Co., Ltd. 
Shanghai RAAS Blood Products Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






